Page 10 - Exscientia News Today

Exscientia’s (NASDAQ:EXAI – Get Rating) lock-up period is set to expire on Wednesday, March 30th. Exscientia had issued 13,850,000 shares in its initial public offering on October 1st. The total size of the offering was $304,700,000 based on an initial share price of $22.00. After the expiration of Exscientia’s lock-up period, restrictions preventing major shareholders […]

Exscientia (NASDAQ:EXAI – Get Rating) announced its earnings results on Wednesday. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.79), Fidelity Earnings reports. Shares of Exscientia stock traded down $0.15 during trading hours on Friday, hitting $14.46. 328 shares of the company’s stock traded […]

Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005753/en/(Graphic: Business Wire) Recent advancements

Company to host conference call and webcast on March 24, 2022 at 12:30 p.m. GMT 8:30 a.m. ET Exscientia (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December

Program open at no-cost to any academic researcher interested in submitting a proposal Exscientia (Nasdaq: EXAI) and the University of Oxford Target Discovery Institute (Oxford TDI) today announced

AI-driven discovery platform enables new way to find novel pathways as well as progress towards identifying patients who may better respond to drugs in the clinic Preclinical data highlights the

The second year of the COVID-19 pandemic saw a wave of global demand for coronavirus tests that finally reached the public markets. Diagnostics companies raised hundreds of millions of, and in some cases over a billion, dollars by pitching Wall Street on their ability to meet that need.

Exscientia (Nasdaq: EXAI) today announced that Andrew Hopkins, DPhil., Exscientia's founder and CEO and Ben Taylor, CFO Chief Strategy Officer, will participate in fireside chats at the following investor

While the U.K. shattered its previous biotech venture capital funding record by 81% in 2021, the continental Europe saw private financing dip by about 12%. Genetic sequencing startup Oxford Nanopore and artificial intelligence drug discoverer Exscientia led the way in both VC fundraising and initial public offering proceeds.

Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Exscientia as Chief Scientist of Biologics AI. In this newly created role, she will focus on the application of artificial intelligence